Predictive value of geriatric nutritional risk index in patients with pancreatic cancer: a meta-analysis

ObjectiveWhile growing evidence supports the Geriatric Nutritional Risk Index (GNRI) as a prognostic indicator for various cancers, its predictive value in pancreatic cancer remains unclear. This meta-analysis systematically evaluates GNRI’s ability to predict postoperative complications and long-te...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaqi Hua, Yi Yuan, Chen Zhou, Liping Liu, Yan Hu, Ping Tu, Dongying Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Nutrition
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fnut.2025.1464447/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveWhile growing evidence supports the Geriatric Nutritional Risk Index (GNRI) as a prognostic indicator for various cancers, its predictive value in pancreatic cancer remains unclear. This meta-analysis systematically evaluates GNRI’s ability to predict postoperative complications and long-term outcomes in pancreatic cancer patients.MethodsWe conducted a comprehensive literature search across nine databases (Web of Science, PubMed, Embase, Cochrane Library, Scopus, WanFang, CNKI, VIP, and SinoMed) through June 1, 2025. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess overall survival (OS), while risk ratios (RRs) with 95% CIs evaluated postoperative complications.ResultsFrom 233 initially identified studies, 10 met inclusion criteria (n = 2,003 patients). Pooled analysis revealed that lower GNRI significantly predicted worse OS (HR = 1.92, 95% CI 1.54–2.41, p < 0.0001) and higher postoperative pancreatic fistula (POPF) incidence (RR = 0.18, 95% CI 0.08–0.43, p < 0.001). No significant association was found between GNRI and post-pancreatectomy hemorrhage (PPH) (RR = 0.21, 95% CI 0.03–1.53, p = 0.13).ConclusionGNRI shows promise as a clinically useful predictor of OS and POPF in pancreatic cancer patients. However, these findings require validation through prospective multicenter studies.Systematic review registrationIdentifier CRD42023409362.
ISSN:2296-861X